reason report
anoth quarter build momentum horizon get
bottom line today market close deliv anoth strong
quarter sale out-performance sale
y/i -- ahead us ahead consensu
repres beat last quarter consecut
notabl ad highest number ever new patient
benefit grow medicar patient popul
on-going transit pharmaci channel manag note
repres instal base today continu
unlock massiv type opportun beat entir driven
omnipod even launch potenti
revolutionari horizon autom insulin deliveri system
enter pivot come week rais sale guidanc
midpoint suggest growth
y/i previous beat
overal clean beat rais quarter reinforc view
drive sustain double-digit growth forese futur
ahead potenti horizon launch believ sale growth
driven continu execut exist growth
vector includ potenti acceler adopt
compani roll dash shift pharmaci channel
believ also acceler intern
instal base direct importantli
underappreci growth opportun insulin-depend type
diabet estim less penetr
 today manag note type
year old expand coverag dash
medicar patient -- coupl pay-as-you-go model
pharmaci channel -- open massiv under-penetrated
reiter op pt pt appli ev/
sale multipl sale estim share
current trade sale estim
expect multipl hold current level given believ
sustain double-digit growth next year
dramat improv profit profil -- consist net incom
posit believ share deserv trade premium
ev/sal multipl smid-cap med-tech coverag univers
outlook move higher updat guidanc
sale estim move y/i
 omnipod sale estim
y/i fall high end guidanc rang expect
adopt momentum sustain
medic suppli devic
sale
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep figur includ fa option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target next year
continu focu drive strong referr momentum expand access
greater awar deliv believ around nearli top-lin
compound-annual-growth-rate time-frame underw manag transit sever
year ago busi stabl to-acceler believ long-term market
opportun pump therapi improv seem adopt inflect
solid execut continu reinvest sale forc appear pois
next month believ share trade pt appli
ev/sal multipl sale estim share current
trade sale estim expect multipl hold current
level given believ sustain double-digit growth next year
dramat improv profit profil -- consist net incom posit believ
share deserv trade premium ev/sal multipl smid-cap
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt svb leerink estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt svb leerink estim
dollar million except per share data
total good sold
research develop expens
loss discontinu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
declin
declin
declin
increas
mid rang
mid rang
mid-low teen growth
mid-low teen growth
teen
 y/i midpoint
dexcom cgm provid
autom glucos control autom
insulin deliveri essenti enabl
omnipod cgm speak one
actual market
two decad
good deliveri system avail eli
lilli launch kwikpen late
pump
avail market
effect increas
capac reservoir enabl
omnipod better serv peopl higher
insulin requir peopl live
insulin depend type diabet
omnipod omnipod
doubl address market
clinic trial on-go
august stare studi enrol
patient expect complet octob
august expect complet trial
move final pre-pivot
august track start pivot
 novemb horizon integr pump/cgm
push late plan
add phone control
start
enrol complet
believ possibl present data
ada
may expect data avail
run clinic trial full
 may expect submit week
 announc fda clearanc use fiasp
fast-act insulin aspart omnipod dash system
adult
